Kiora Pharmaceuticals

Home
United States
Encinitas, CA
Kiora Pharmaceuticals

Clinical stage biotech company focusing on novel therapeutics for the treatment of retinal diseases Kiora Pharmaceuticals, Inc.

(Kiora) is a clinical development-stage company focusing on novel therapeutics for the treatment of orphan retinal diseases with high unmet need. Publicly traded on the NASDAQ under KPRX, our mission is to help patients improve their ocular health and restore vision.

02/19/2026

As part of the ongoing ABACUS-2 Phase 2 trial, a potential new treatment is being evaluated for its safety and potential impact on vision in later-stage Retinitis Pigmentosa (RP)—an inherited retinal condition that can lead to complete blindness. If successful, it may become the ﬁrst treatment option for patients with this rare inherited disease.

This investigational small molecule therapy is being studied for its ability to improve vision in people with advanced RP.

🧬 Targets retinal ganglion cells
🔬 Trial targets those with advanced photoreceptor loss

Please note: Certain statements about this potential new treatment are forward-looking and involve risks and uncertainties.

Learn more at: https://kiorapharma.com/pipeline-science/kio-301/ .

02/18/2026

At Kiora Pharmaceuticals, our work is driven by a simple belief: improving vision has the power to improve lives.

Through advanced clinical research in ophthalmology, we’re committed to exploring new approaches that may support people living with inherited and acquired retinal diseases.

Learn how we continue to develop science designed to make a meaningful difference for patients and their families at kiorapharma.com

02/12/2026

A powerful perspective from Brian M. Strem, PhD, Chief Executive Officer at Kiora Pharmaceuticals, on what restored navigation and independence could mean for people living with severe vision loss. Our team is advancing research in molecular photoswitch technology with the goal of developing new options for individuals affected by inherited retinal diseases.

Learn more about our work at kiorapharma.com

02/05/2026

Macular edema can cause blurred, distorted, or reduced central vision. It's often caused by conditions including uveitis, diabetic retinopathy, or retinal vein occlusion.

The KLARITY-1 trial is a Phase 2 study evaluating the safety and possible benefits of a potential new treatment—an investigational intravitreal injection for macular edema.

🔍 The treatment is delivered directly into the eye every 2–4 weeks.
👁️ The goal is to reduce swelling and improve visual acuity.
📍 The study is taking place at sites across Australia.

Participants are closely monitored throughout the study and contribute valuable insight into a condition that deserves expanding and effective treatment options.

Learn more at: https://bit.ly/KioraHome.

02/04/2026

Inherited retinal diseases (IRDs) make up a diverse group of conditions caused by genetic changes ultimately impacting how the retina functions.

While each condition is unique, IRDs share a similar challenge: progressive vision loss.

At Kiora Pharmaceuticals, we’re working to address this challenge through KIO-301, an investigational molecular photoswitch designed to target late-stage vision loss in conditions such as Retinitis Pigmentosa, Choroideremia, and Stargardt Disease.

Learn more about KIO-301 at https://kiorapharma.com/pipeline-science/kio-301/

02/03/2026

Macular edema can cause blurred or distorted vision — but new research is underway to ﬁnd additional solutions to address this condition.

KLARITY-1 — a Phase 2 clinical trial evaluating the safety and effectiveness of a potential new treatment—an investigational treatment administered via intravitreal injection. The trial explores how this potential new treatment may reduce macular swelling and improve vision in patients with macular edema caused by conditions including:

- Diabetic retinopathy
- Non-infectious uveitis
- Retinal vein occlusion
- Cataract surgery

Learn more at: https://bit.ly/KioraHome.

01/27/2026

KIO-301 is an investigational small molecule being studied for its ability to improve vision in people with advanced Retinitis Pigmentosa (RP) — an inherited retinal condition that can lead to complete blindness.

As part of the ongoing ABACUS-2 Phase 2 trial, KIO-301 is being evaluated for its safety and potential impact on vision in later-stage RP. If successful, it may become the ﬁrst treatment option for patients with this rare inherited disease.

🧬 Targets retinal ganglion cells
🔬 Trial targets those with advanced photoreceptor loss

Please note: Certain statements about KIO-301 are forward-looking and involve risks and uncertainties.

Learn more at: https://bit.ly/KioraHome.

01/21/2026

Macular edema can cause blurred, distorted, or reduced central vision. It's often linked to conditions like uveitis, diabetic retinopathy, or retinal vein occlusion.

The KLARITY-1 trial is a Phase 2 study evaluating the safety and potential benefits of KIO-104, an investigational intravitreal injection for macular edema.

🔍 The treatment is delivered directly into the eye every 2–4 weeks.
👁️ The goal is to reduce swelling and improve visual acuity.
📍 The study is taking place at sites across Australia.

Participants are closely monitored throughout the study and contribute valuable insight into a condition that deserves consistently effective treatment options.

Learn more at: https://bit.ly/KioraHome.

01/13/2026

Macular edema can cause blurred or distorted vision — but new research is underway to ﬁnd better solutions to address this condition.

KLARITY-1 — a Phase 2 clinical trial evaluating the safety and effectiveness of KIO-104, an investigational treatment administered via intravitreal injection. The trial explores how KIO-104 may reduce macular swelling and improve vision in patients with macular edema caused by conditions including:

● Diabetic retinopathy

● Non-infectious uveitis

● Retinal vein occlusion

● Cataract surgery

Learn more at: https://bit.ly/KioraHome.

01/07/2026

This is KIO-301: a molecular photoswitch designed to help restore vision in people living with inherited retinal diseases such as retinitis pigmentosa. By turning light signals “on” and “off” within the eye, this investigational therapy aims to restore the ability to sense light where it’s been lost.

It’s science with one goal: turning light into hope.

Learn more about KIO-301 at https://kiorapharma.com/pipeline-science/kio-301/

12/30/2025

At Kiora Pharmaceuticals, our mission is simple yet powerful: to restore sight and renew hope for people living with inherited and acquired retinal diseases. Through science rooted in innovation and compassion, we’re developing therapies that aim to bring light back to lives touched by vision loss.

Vision loss changes more than how someone sees the world — it changes how they experience it. That’s why we’re committed to developing innovative therapies that do more than address conditions; they aim to bring light, connection, and independence back into people’s lives.

Learn more about our mission at https://kiorapharma.com/

12/23/2025

KIO-104 is an investigational therapy designed to target inﬂammation in the retina without relying on steroids or systemic drugs. It works by inhibiting DHODH, an enzyme critical for T-cell replication and function, which helps reduce damaging immune activity in the eye. Currently, it’s being studied in the Phase 2 KLARITY-1 trial for conditions like uveitis and diabetic macular edema.

Learn more about KIO-104 at https://kiorapharma.com/pipeline-science/kio-104/

Address

332 Encinitas Boulevard, Suite 102
Encinitas, CA
92024

Website

http://kiorapharma.com/

Alerts

Be the first to know and let us send you an email when Kiora Pharmaceuticals posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Kiora Pharmaceuticals:

Shortcuts

Want your practice to be the top-listed Clinic in Encinitas?